1-20 of 129
Xi Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer

Jeremy B. Foote, Tyler E. Mattox, Adam B. Keeton, Xi Chen, Forrest T. Smith, Kristy Berry, Thomas W. Holmes, Junwei Wang, Chung-hui Huang, Antonio Ward, Amit K. Mitra, Veronica Ramirez-Alcantara, Cherlene Hardy, Karianne G. Fleten, Kjersti Flatmark, Karina J. Yoon, Sujith Sarvesh, Ganji P. Nagaraju, Dhana Sekhar Reddy Bandi, Yulia Y. Maxuitenko, Jacob Valiyaveettil, Julienne L. Carstens, Donald J. Buchsbaum, Jennifer Yang, Gang Zhou, Elmar Nurmemmedov, Ivan Babic, Vadim Gaponeko, Hazem Abdelkarim, Michael R. Boyd, Greg Gorman, Upender Manne, Sejong Bae, Bassel F. El-Rayes, Gary A. Piazza
Journal: Cancer Research
Cancer Res (2025) 85 (5): 956–972.
https://doi.org/10.1158/0008-5472.CAN-24-0323
Published: 03 March 2025
View article titled, A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
Open the PDF for A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PR-18: RNF43 Loss Induces an IRE1-dependent Metabolic Reprogramming in Pancreatic Cystic Neoplasms

Akiko Sagara, Xiangdong Lv, Brandon Chen, Yuki Makino, Shui Ping So, Sonja M Woermann, Costas A Lyssiotis, Yatrik M Shah, Bidyut Ghosh, Xi Chen, Johannes F Fahrmann, Anirban Maitra
Journal: Cancer Research
Cancer Res (2024) 84 (17_Supplement_2): PR-18.
https://doi.org/10.1158/1538-7445.PANCREATIC24-PR-18
Published: 15 September 2024
View article titled, Abstract PR-18: RNF43 Loss Induces an IRE1-dependent Metabolic Reprogramming in Pancreatic Cystic Neoplasms
Journal Articles

Abstract C027: Efficacy advantages of a novel pan-RAS inhibitor, ADT-1004, over mutant- specific KRAS inhibitors for suppressing pancreatic tumor growth in murine models

Dhana Sekhar Reddy Bandi, Ganji P Nagaraju, Jeremy B Foote, Adam B Keeton, Xi Chen, Kristy L Berry, Yulia Y Maxuitenko, Upender Manne, Donald J Buchsbaum, Gary A Piazza, Bassel F El-Rayes
Journal: Cancer Research
Cancer Res (2024) 84 (17_Supplement_2): C027.
https://doi.org/10.1158/1538-7445.PANCREATIC24-C027
Published: 15 September 2024
View article titled, Abstract C027: Efficacy advantages of a novel pan-RAS inhibitor, ADT-1004, over mutant- specific KRAS inhibitors for suppressing pancreatic tumor growth in murine models
Journal Articles

Abstract C025: A novel pan-RAS/β-catenin inhibitor, ADT-030, produces tumor regression in PDX models of pancreatic cancer

Dhana Sekhar Reddy Bandi, Ganji P Nagaraju, Jeremy B Foote, Adam B Keeton, Xi Chen, Kristy L Berry, Yulia Y Maxuitenko, Upender Manne, Donald J Buchsbaum, Gary A Piazza, Bassel F El-Rayes
Journal: Cancer Research
Cancer Res (2024) 84 (17_Supplement_2): C025.
https://doi.org/10.1158/1538-7445.PANCREATIC24-C025
Published: 15 September 2024
View article titled, Abstract C025: A novel pan-RAS/β-catenin inhibitor, ADT-030, produces tumor regression in PDX models of pancreatic cancer
Journal Articles

Abstract GS01-08: CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer

Ze-Yi Zheng, Anran Chen, Eric Jaehnig, Meenakshi Anurag, Jonathan Lei, Chenwei Wang, Long Feng, Purba Singh, Hilda Kennedy, Jin Cao, Ghazal Yadav, Jill Tsai, Xi Chen, Charles Foulds, Bora Lim, Matthew Ellis, Bing Zhang, Eric Chang
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): GS01-08.
https://doi.org/10.1158/1538-7445.SABCS23-GS01-08
Published: 02 May 2024
View article titled, Abstract GS01-08: CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer
Journal Articles

Abstract CT235: RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 study of 1L bevacizumab + pemetrexed/paclitaxel ± atezolizumab in metastatic NSCLC

Caicun Zhou, Charlie Sun, Stacey Huang, Xiaorong Dong, Gongyan Chen, Zhehai Wang, Xianghua Wu, Yu Yao, Yiping Zhang, Ying Cheng, Hongming Pan, Xiaodong Zhang, Jiuwei Cui, Lifeng Wang, Xi Chen, Xiaoling Li, Ziping Wang, Qiming Wang, Jianxing He, Mengzhao Wang, Li Qian, Habib Hamidi, Shanshan Li, Marcus Ballinger, David S. Shames, Minu Srivastava
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT235.
https://doi.org/10.1158/1538-7445.AM2024-CT235
Published: 05 April 2024
View article titled, Abstract CT235: RNA-seq molecular subtypes and gene expression signatures in the phase 3 IMpower151 study of 1L bevacizumab + pemetrexed/paclitaxel ± atezolizumab in metastatic NSCLC
Journal Articles

Abstract LB100: Performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort

Vladimir Gainullin, Hee Jung Hwang, Larson Hogstrom, Kevin Arvai, Amira Best, Melissa Gray, Madhav Kumar, Mael Manesse, Xi Chen, Philip Uren, Amin Mazloom, Gustavo Cerqueira, Jorge Garces, Tomasz M. Beer, Abigail Mcelhinny, Frank Diehl
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): LB100.
https://doi.org/10.1158/1538-7445.AM2024-LB100
Published: 05 April 2024
View article titled, Abstract LB100: Performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively-collected cohort
Journal Articles

Abstract LB272: Sequential inhibition of PARP and BET as a rational therapeutic strategy for glioblastoma multiforme

Xin Peng, Xin Huang, Shaolu Zhang, Naixin Zhang, Shengfan Huang, Yingying Wang, Zhenxing Zhong, Shan Zhu, Haiwang Gao, Zixiang Yu, Xiaotong Yan, Zhennan Tao, Yuxiang Dai, Zhe Zhang, Xi Chen, Feng Wang, Francois X. Claret, Ning Ji, Yuxu Zhong, Dexin Kong
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): LB272.
https://doi.org/10.1158/1538-7445.AM2024-LB272
Published: 05 April 2024
View article titled, Abstract LB272: Sequential inhibition of PARP and BET as a rational therapeutic strategy for glioblastoma multiforme
Journal Articles

Abstract 5915: ADT-1004: A promising pan-RAS inhibitor for targeting KRAS mutations in pancreatic ductal adenocarcinoma

Dhana Sekhar Reddy Bandi, Purnachandra Nagaraju Ganji, Sujith Sarvesh, Yulia Maxuitenko, Jeremy B Foote, Adam B Keeton, Xi Chen, Donald Buchsbaum, Gary Piazza, Bassel El-Rayes
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5915.
https://doi.org/10.1158/1538-7445.AM2024-5915
Published: 22 March 2024
View article titled, Abstract 5915: ADT-1004: A promising pan-RAS inhibitor for targeting KRAS mutations in pancreatic ductal adenocarcinoma
Journal Articles

Abstract 3323: Novel Pan-RAS inhibitor ADT-007: A unique mechanism of antitumor selectivity in pancreatic and colorectal carcinoma models

Junwei Wang, Adam B. Keeton, Sindhu Ramesh, Peyton Johnson, Yulia Y. Maxuitenko, Jeremy B. Foote, Chung-Hui Huang, Kristy L. Berry, Khalda Fadlalla, Bandi D. Reddy, Ganji P. Nagaraju, Elmar Nurmemmedov, Ivan Babic, Vadim Gaponenko, Xi Chen, Bassel F. El-Rayes, Donald J. Buchsbaum, Gary A. Piazza
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3323.
https://doi.org/10.1158/1538-7445.AM2024-3323
Published: 22 March 2024
View article titled, Abstract 3323: Novel Pan-RAS inhibitor ADT-007: A unique mechanism of antitumor selectivity in pancreatic and colorectal carcinoma models
Journal Articles

Abstract 1750: Decoding breast cancer: Unraveling subtype and model differences through multi-model single-cell RNA sequencing data integration

Julia E. Altman, Carson J. Walker, Emily K. Zboril, Nicole S. Hairr, Rachel K. Myrick, David C. Boyd, Jennifer E. Koblenski, Madhavi Puchalapalli, Bin Hu, Mikhail G. Dozmorov, Xi Chen, Yunshun Chen, Charles M. Perou, Brian D. Lehmann, Jane E. Visvader, Amy L. Olex, J. Chuck Harrell
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1750.
https://doi.org/10.1158/1538-7445.AM2024-1750
Published: 22 March 2024
View article titled, Abstract 1750: Decoding breast cancer: Unraveling subtype and model differences through multi-model single-cell RNA sequencing data integration
Journal Articles

Abstract 2459: ADT-030 is a novel dual-acting RAS/β-catenin inhibitor that potentiates antitumor immunity

Md Yeashin Gazi, Ogacheko Okoko, Xin Wang, Caitlin Brandle, Xi Chen, Khalda Fadlalla, Adam Keeton, Yulia Maxuitenko, Catherine Hedrick, Huidong Shi, Gary Piazza, Gang Zhou
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2459.
https://doi.org/10.1158/1538-7445.AM2024-2459
Published: 22 March 2024
View article titled, Abstract 2459: ADT-030 is a novel dual-acting RAS/β-catenin inhibitor that potentiates antitumor immunity
Journal Articles

Abstract 7165: Clinical population pharmacokinetic (popPK) analysis of NBF-006, a novel siRNA inhibitor of glutathione-S-transferase P (GSTP) encapsulated in a lipid nano particle (LNP), for treatment of advanced non-small cell lung cancer (NSCLC)

Michael P. Hall, Zhihong O'Brien, Xi Chen, Angelean Hendrix, Stacy Brenes-Coto, Sonya Zabludoff
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7165.
https://doi.org/10.1158/1538-7445.AM2024-7165
Published: 22 March 2024
View article titled, Abstract 7165: Clinical population pharmacokinetic (popPK) analysis of NBF-006, a novel siRNA inhibitor of glutathione-S-transferase P (GSTP) encapsulated in a lipid nano particle (LNP), for treatment of advanced non-small cell lung cancer (NSCLC)
Journal Articles

Abstract B038: A preliminary study on predicting pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer

Xi Chen, Zhiguo Zhou
Journal: Cancer Research
Cancer Res (2024) 84 (3_Supplement_2): B038.
https://doi.org/10.1158/1538-7445.CANEVOL23-B038
Published: 01 February 2024
View article titled, Abstract B038: A preliminary study on predicting pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
Journal Articles

Abstract CT021: Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ianalumab (VAY736) + ibrutinib

Kerry Anne Rogers, Pearlly Yan, Ian W. Flinn, Deborah M. Stephens, Thomas J. Kipps, Sarah M. Larson, Laura Martz, Xi Chen, Huabao Wang, Ethan Hopping, Ralf Bundschuh, Alexandra Acosta, Daniela Baldoni, Anwesha Chaudhury, Jeanne Whalen, Nadia B. Hassounah, Nina Orwitz, Janghee Woo, John C. Byrd
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT021.
https://doi.org/10.1158/1538-7445.AM2023-CT021
Published: 14 April 2023
View article titled, Abstract CT021: Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ianalumab (VAY736) + ibrutinib
Journal Articles

Abstract LB322: Antitumor activity of 1st-in-class pan-RAS inhibitor ADT-1004 in mouse models of pancreatic ductal adenocarcinoma

Yulia Y. Maxuitenko, Jeremy B. Foote, Adam B. Keeton, Xi Chen, Kristy Berry, Khalda Fadlalla, Jacob Valiyaveettil, Chung-Hui Huang, Austin M. Moore, Emily C. Graff, Ganji P. Nagaraju, Julienne L. Carstens, Bassel F. El-Rayes, Donald J. Buchsbaum, Gary A. Piazza
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): LB322.
https://doi.org/10.1158/1538-7445.AM2023-LB322
Published: 14 April 2023
View article titled, Abstract LB322: Antitumor activity of 1st-in-class pan-RAS inhibitor ADT-1004 in mouse models of pancreatic ductal adenocarcinoma
Journal Articles

Abstract 3089: XNW5004: a novel EZH2 inhibitor efficacious in multiple cancer xenograft models as a single agent and in combination studies

Yonghan Hu, Wei Peng, Zhe Zhang, Zhenwei Wu, Xi Chen, Yan Huang, Xin Li, Cungang Liu, Xiaojun Liu, Qifeng Shi, Xufang Wang, Wengui Wang, Haiyang Wei, Yuchuan Wu, Jun Xian, Linfeng Xu, Lina Zhang, Jinfeng Zhao, Meijie Le, Jing Qiang
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3089.
https://doi.org/10.1158/1538-7445.AM2023-3089
Published: 04 April 2023
View article titled, Abstract 3089: XNW5004: a novel EZH2 inhibitor efficacious in multiple cancer xenograft models as a single agent and in combination studies
Journal Articles

Abstract 478: A novel dual-acting RAS/β-catenin inhibitor activates antitumor immunity to potentiate cancer immunotherapy

Md Yeashin Gazi, Ogacheko Okoko, Xin Wang, Caitlin Brandle, Zhi-chun Ding, Amit Mitra, Veronica Ramirez-Alcantara, Xi Chen, Adam Keeton, Yulia Maxuitenko, Gary Piazza, Gang Zhou
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 478.
https://doi.org/10.1158/1538-7445.AM2023-478
Published: 04 April 2023
View article titled, Abstract 478: A novel dual-acting RAS/β-catenin inhibitor activates antitumor immunity to potentiate cancer immunotherapy
Journal Articles

Abstract 477: Discovery of RGT-018: A potent, selective and orally bioavailable SOS1 inhibitor for mutant KRAS-driven cancers

Fei Xiao, Kailiang Wang, Xinjuan Wang, Huijuan Li, Zhilong Hu, Wei Huang, Xiaoming Ren, Teng Feng, Lili Yao, Jing Lin, Chunlai Li, Liufeng Mei, Zhuanzhuan Zhang, Yangyang Liu, Xi Chen, Xiaotian Zhu, Wenge Zhong, Zhi Xie
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 477.
https://doi.org/10.1158/1538-7445.AM2023-477
Published: 04 April 2023
View article titled, Abstract 477: Discovery of RGT-018: A potent, selective and orally bioavailable SOS1 inhibitor for mutant KRAS-driven cancers
Journal Articles

Abstract 5831: CD200R signaling contributes to unfavorable tumor microenvironment through regulating production of chemokines by tumor associated macrophages

Cho-Hao Lin, Fatemeh Talebian, Yang Li, Jianmin Zhu, Bolin Zhao, Jin-Qing Liu, Sujit Basu, Xueling Pan, Xi Chen, Pearlly Yan, William E. Carson, Gang Xin, Haitao Wen, Ruoning Wang, Zihai Li, Qin Ma, Xue-Feng Bai
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5831.
https://doi.org/10.1158/1538-7445.AM2023-5831
Published: 04 April 2023
View article titled, Abstract 5831: CD200R signaling contributes to unfavorable tumor microenvironment through regulating production of chemokines by tumor associated macrophages